Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will be using an AUC of 6 based on creatinine clearance using
the Carboplatin dosing formula used for Gynecologic Oncology Group protocols.
Given that myelosuppression was significant using the docetaxel dose of 75 mg/m*2 in the
SCOTROC trial, the prophylactic use of pegylated G-CSF in this Phase II trial is warranted.
The expectation would be that patients will be able to receive their cycles in a more timely
fashion, with less delays, thereby allowing for improved outcomes and decreased
hospitalizations due to myelosuppression.